Once-Weekly Insulin Approved: 4 Essential Facts for Type 2 Diabetes
A once-weekly insulin for type 2 diabetes is now FDA-approved. On September 24, 2026, Eli Lilly announced U.S. approval of Onswik (insulin efsitora alfa), a basal insulin you inject just once a week. For the millions of older adults who take daily insulin, that could mean more than 300 fewer injections per year. Here is what this breakthrough means for you.
Why Does a Once-Weekly Insulin Matter to You?
Diabetes is overwhelmingly a condition of later life. According to the CDC, roughly 29% of Americans 65 and older have diabetes, and most cases are type 2.
Daily shots are a real burden. Many people delay starting insulin because of them, and missed doses are common when eyesight, memory or arthritis make injections harder.
A weekly schedule is simpler to remember. It may also be easier for a spouse or caregiver to help with one dose a week than with a shot every single day.
For people juggling several prescriptions, a once-weekly insulin removes one daily task from a crowded routine. That can reduce stress, travel hassle and the chance of a skipped dose.
Key Facts About the Onswik Approval
- Dosing: One injection a week (52 per year) versus 365 for a once-daily basal insulin.
- Evidence: The QWINT Phase 3 trials enrolled more than 3,400 adults with type 2 diabetes. Onswik lowered A1C about as well as daily insulin glargine or degludec.
- Safety: Its overall safety profile was similar to daily basal insulins. Low blood sugar remains the most important side effect.
- Timing: Lilly says the Onswik KwikPen will reach U.S. pharmacies “in the coming months.”
Onswik is not for people with type 1 diabetes. It was already approved in Europe, Mexico and Japan before the FDA decision, according to Lilly’s announcement.
What This Means for You
A new option does not mean you should switch right away. Use these steps to decide whether a weekly basal insulin fits your routine.
Should You Ask Your Doctor About Switching?
If daily injections are hard to keep up with, bring it up at your next visit. Ask whether your A1C, kidney function and other medicines make you a good candidate. Your doctor may also weigh newer non-insulin drugs first.
Will Medicare Cover It?
Coverage is not set yet. Once Onswik launches, call your Part D plan and ask whether it is on the formulary. The $35 monthly insulin cap applies to covered insulins, so formulary status matters. Our guide to the Senate bill targeting drug cost middlemen explains why your out-of-pocket price can vary so much.
How Can You Stay Safe With a Weekly Dose?
The pen comes in two strengths (U-500 and U-1,000), so dosing errors are a key risk. Always check the label and have your doctor or pharmacist demonstrate the pen. Keep glucose tablets handy and learn the signs of low blood sugar: shakiness, sweating, confusion and blurred vision.
Tracking a weekly dose is easier with a simple routine. Pick the same day each week, set a phone alarm and keep a written log so you or a caregiver can confirm each dose.
Looking Forward
Onswik is part of a bigger shift toward fewer, simpler treatments for chronic conditions. Weekly GLP-1 drugs already changed how many people manage blood sugar, and a once-weekly insulin extends that convenience to basal insulin users. As it reaches pharmacies, expect questions about price, insurance coverage and who benefits most.
For now, the takeaway is simple: if daily insulin feels like a chore, a proven weekly alternative is on the way. Start the conversation with your doctor now. For more on heart and metabolic health after 70, read our coverage of the statin trial that cut heart attack risk 30% and the latest longevity breakthroughs of 2026.
This article is for information only and is not medical advice. Talk with your healthcare provider before changing any medication.